The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10054 malaria professionals are enjoying the free benefits of MalariaWorld today

artemisinin combination therapies (ACTs)

NOT Open Access | Artemisone and Artemiside Are Potent Panreactive Antimalarial Agents That Also Synergize Redox Imbalance in Plasmodium falciparum Transmissible Gametocyte Stages

August 1, 2018 - 14:39 -- NOT Open Access
Author(s): 
Dina Coertzen, Janette Reader, Richard K. Haynes, et al.
Reference: 
Antimicrob. Agents Chemother. August 2018 vol. 62 no. 8 e02214-17

The emergence of resistance toward artemisinin combination therapies (ACTs) by the malaria parasite Plasmodium falciparum has the potential to severely compromise malaria control.

NOT Open Access | Little Polymorphism at the K13 Propeller Locus in Worldwide Plasmodium falciparum Populations Prior to the Introduction of Artemisinin Combination Therapies

May 25, 2016 - 17:52 -- NOT Open Access
Author(s): 
Toshihiro Mita, Richard Culleton, Jun Ohashi, et al.
Reference: 
Antimicrob. Agents Chemother. June 2016 vol. 60 no. 6 3340-3347

The emergence and spread of artemisinin-resistant Plasmodium falciparum is of huge concern for the global effort toward malaria control and elimination.

Caregivers’ treatment-seeking behaviors and practices in Uganda—A systematic review (Part II)

November 10, 2015 - 05:25 -- Open Access
Author(s): 
Rosemin Kassam, John B. Collins, Eric Liow, Nabeela Rasool
Reference: 
Acta Tropica, Volume 152, December 2015, Pages 269–281

Prompt treatment with artemisinin combination therapies (ACTs) remains the cornerstone for managing uncomplicated malaria caused by Plasmodium falciparum.

Country: 

NOT Open Access | Understanding artemisinin-resistant malaria: what a difference a year makes

September 3, 2015 - 14:42 -- NOT Open Access
Author(s): 
Fairhurst, Rick M.
Reference: 
Current Opinion in Infectious Diseases:, October 2015 - Volume 28 - Issue 5 - p 417–425

In SEA, clinical and epidemiological investigations are urgently needed to stop the further spread of artemisinin resistance, monitor the efficacy of ACTs where K13 mutations are prevalent, identify currently-available drug regimens that cure ACT failures, and rapidly advance new antimalarial compounds through preclinical studies and clinical trials.

Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries

May 13, 2015 - 11:19 -- Open Access
Tags: 
Author(s): 
Benjamin Palafox, Edith Patouillard, Desmond Chavasse, et al.
Reference: 
Health Policy and Planning, Date: May 5, 2015

The private for-profit sector is an important source of treatment for malaria.

NOT Open Access | Therapeutic Responses of Plasmodium vivax Malaria to Chloroquine and Primaquine Treatment in Northeastern Myanmar

January 28, 2015 - 16:17 -- NOT Open Access
Author(s): 
Lili Yuan, Ying Wang, Liwang Cui, et al.
Reference: 
Antimicrob. Agents Chemother. February 2015 vol. 59 no. 2 1230-1235

Chloroquine-primaquine (CQ-PQ) continues to be the frontline therapy for radical cure of Plasmodium vivax malaria.

Artemisinin-Naphthoquine versus Artemether-Lumefantrine for Uncomplicated Malaria in Papua New Guinean Children: An Open-Label Randomized Trial

January 7, 2015 - 10:13 -- Open Access
Tags: 
Author(s): 
Moses Laman, Brioni R. Moore, Timothy M. E. Davis, et al.
Reference: 
PLoS Med 11(12): e1001773

Artemisinin-naphthoquine is non-inferior to artemether-lumefantrine in PNG children with falciparum malaria but has greater efficacy against vivax malaria, findings with implications in similar geo-epidemiologic settings within and beyond Oceania.

Efficacy and Safety of Fixed-Dose Artesunate-Amodiaquine vs. Artemether-Lumefantrine for Repeated Treatment of Uncomplicated Malaria in Ugandan Children

December 18, 2014 - 06:15 -- Open Access
Tags: 
Author(s): 
Adoke Yeka, Valerie Lameyre, Kibuuka Afizi, Mudangha Fredrick, Robinson Lukwago, Moses R. Kamya, Ambrose O. Talisuna
Reference: 
PLoS ONE 9(12): e113311

The safety and efficacy of the two most widely used fixed-dose artemisinin-based combination therapies (ACT), artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) are well established for single episodes of uncomplicated Plasmodium falciparum malaria, but the effects of repeated, long-term use are not well documented.

Person: 
Country: 

Ex Vivo Activity of Endoperoxide Antimalarials, Including Artemisone and Arterolane, against Multidrug-Resistant Plasmodium falciparum Isolates from Cambodia

September 19, 2014 - 15:02 -- Open Access
Author(s): 
Charlotte A. Lanteri, Suwanna Chaorattanakawee, Chanthap Lon, David L. Saunders, Wiriya Rutvisuttinunt, Kritsanai Yingyuen, Ian Bathurst, Xavier C. Ding, and Stuart D. Tyner
Reference: 
Antimicrob. Agents Chemother. October 2014 vol. 58 no. 10 5831-5840

Novel synthetic endoperoxides are being evaluated as new components of artemisinin combination therapies (ACTs) to treat artemisinin-resistant Plasmodium falciparum malaria.

Subscribe to RSS - artemisinin combination therapies (ACTs)